Rockville, MD, USA (8 July 2003), PATH’s Malaria Vaccine Initiative (MVI), GlaxoSmithKline Biologicals (GSK Bio) and the Swiss Tropical Institute (STI) today announced a new partnership to research the potential impact of future malaria vaccines on the global disease burden. Using existing malaria vaccine candidates—including GSK Bio’s RTS,S/AS02A—as models, STI will explore the effects of malaria vaccination and current malaria control strategies on Plasmodium falciparum malaria, the leading cause of death among African children under the age of five.
The modeling study will help inform scientific decisions related to malaria vaccine research and development, ensuring that field realities are taken into consideration. Companies also will be able to use the study results in strategic decision-making about malaria vaccine demand forecasting and manufacturing capacity. In the future, the model is expected to serve as a tool to help national governments determine how malaria vaccines fit into their immunization and integrated malaria control programs.
For more information, contact info@malariavaccine.org.
###
The Malaria Vaccine Initiative is a global program established through an initial grant from the Bill & Melinda Gates Foundation to Program for Appropriate Technology in Health (PATH) (www.path.org). For more information, visit www.malariavaccine.org.
The Swiss Tropical Institute is an associated institute of the University of Basel and is the national reference center for Tropical and International Health in Switzerland. For more information, visit www.sti.ch.
GlaxoSmithKline Biologicals is the world’s leading vaccine manufacturer. In 2002, an average of 25 GSK Biologicals vaccine doses per second were delivered to 156 countries in both the industrialized and developing world. For more information, visit GSK Biologicals’ vaccine Web site at www.gsk-bio.com.
This page displays best in a browser that supports current web standards, but all content is accessible via any web device.
